INFU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InfuSystem Holdings Inc (INFU) appears to be a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, bullish technical indicators, and positive analyst sentiment outweigh the lack of recent news and hedge fund selling trends. With no significant negative catalysts and a stable growth trajectory, the stock aligns well with the user's investment profile.
The technical indicators are bullish. The MACD is positive and expanding (0.0547), indicating upward momentum. The RSI is at 77.224, in the neutral zone but leaning towards overbought territory. Moving averages show a bullish trend (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 10.171 and 10.499, with support at 9.109 and 8.781.
Strong financial performance in Q4 2025: Revenue increased by 7.04% YoY, net income surged by 118.22% YoY, and EPS rose by 150.00% YoY.
Analysts have raised price targets (Lake Street to $17.50 and Roth Capital to $
and maintain Buy ratings.
Bullish technical indicators suggest a favorable price trend.
Hedge funds are selling, with a significant increase in selling activity (1158.53% over the last quarter).
No recent news or congress trading data to act as additional positive sentiment drivers.
In Q4 2025, InfuSystem reported revenue of $36.23M (+7.04% YoY), net income of $2.036M (+118.22% YoY), EPS of $0.1 (+150.00% YoY), and gross margin of 55.82% (+5.16% YoY). This demonstrates strong growth and profitability improvements.
Analysts are bullish on INFU. Lake Street raised the price target to $17.50, citing confidence in management and high ROIC potential. Roth Capital raised the target to $15, highlighting above-consensus Q4 results and growth in oncology and wound care divisions.
